Kopran Limited · NSE:KOPRAN
Kopran — Q4 FY2021 Earnings Presentation
24 slides from Kopran's earnings presentation, Jun 11, 2021
Slide 1: Cover letter to stock exchanges: Investors Presentation
11th June, 2021 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol : KOPRAN Dear Si
Slide 2: Kopran Limited Quarterly Presentation June 2021
An Integrated Global Pharmaceutical Company Growth-Driven. Future-Focused. Kopran Limited Quarterly Presentation JUNE 2021 NSE ticker: KOPRAN BSE ticker: 524280 Bloomberg ticker: KOP:IN A Parijat Enterprise Company
Slide 3: Safe Harbour Statement
Safe Harbour Statement 2 This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered
Slide 4: Kopran Limited: A Global Pharmaceutical Company
Kopran Limited A Global Pharmaceutical Company 3 Who we are? An integrated pharmaceutical Company, committed to supply International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally State-of-the-art manufacturing facilities and products with various accreditations and appro
Slide 5: APIs Business Overview
APIs Business Overview 4 Kopran Research Laboratories Ltd. Dedicated and versatile Product Segments, facilities for: Anti-hypertensive Atenolol Macrolides Pregabalin Neuromodulator Cephalosporins - Non-Sterile Urological & Sterile Anti-infective/Anti-acne Macrolides Sterile Carbapenems Granules Faci
Slide 6: APIs Focus Areas
APIs Focus Areas 5 Process and yield improvement: Initiatives undertaken continuously for improving the existing product line US and other Regulated markets Emphasis on exports: Leveraging expertise and capabilities by exploring, • 7 USDMF Filed (Atenolol, Pregabalin, developing and commercialising
Slide 7: APIs Products Developed/Under Development
APIs Products Developed/Under Development 6 Products under Pipeline Therapeutic Category R&D Scaleup Validation Commercialization Biapenem Carbapenem Completed Completed Completed Q2 FY 21-22 Tebipenem Carbapenem Completed Completed Completed Faropenem# Carbapenem Completed Completed Completed Q3 FY
Slide 8: APIs Segment-wise Revenue Mix
Operational Highlights APIs Segment-wise Revenue Mix 7 Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs) Advance Intermediate Steriles Advance Intermediate Cepholosphorin Urological Urological Steriles 43.02 -11.14 105.84 Cepholosphorin 702.83 Anti-hypertensive 1,153.85 Anti-hypertensive 832.15 363.63
Slide 9: APIs Market-wise Revenue Mix
Operational Highlights APIs Market-wise Revenue mix 8 Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs) Local Sales 2,790.88 Local Sales 1,640.09 Export Sales Export Sales 4,952.91 5,374.83 Total ₹ 6,593 Lakhs Total ₹ 8,165.71 Lakhs
Slide 10: Way Forward
Way Forward 9 Develop niche and blockbuster products: Improve facility and enhance capacity: Developing complete range of Carbapenams to solidify the Undertook upgradation and expansion of 3 blocks at Mahad facility in Company’s position in the segment Q4 to cater the increasing demand of existing p
Slide 11: Formulations Business Overview
Formulations Business Overview 10 Accreditations: Kopran Limited Approved by 12 countries including MHRA (UK), SAPHRA South Africa (formerly MCC), TMDA Tanzania (formerly TFDA), NDA Uganda, PPB Kenya, MCAZ Dedicated Facilities: Zimbabwe, MOH Oman, MOH Iraq, FMHACA Ethiopia, MOH Penicillin-based Fini
Slide 12: Formulations Focus Areas and Output
Formulations Focus Areas and Output 11 Process/Technology and Yield Improvement: Development of Products and Dossiers for Continuous measures taken towards process/technology and yield Non-Regulated Market: improvement for making products more competitive and profitable Develop products/formulations
Slide 13: Formulations Region-wise Sales Break-up
Operational Highlights Formulations Region-wise Sales Break-up 12 Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs) Southeast UK UK Southeast Asia Asia 427.96 472.16 433.22 361.1 South South Africa 1,249.37 Africa 931.61 39.55 Local 28.23 Local 3,470.47 Africa Latem 46.79 125.56 Latem 2,732.58 Africa
Slide 14: Formulations Product-wise Sales Break-up
Operational Highlights Formulations Product-wise Sales Break-up 13 Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs) Pen Plant 1,047.35 2,027.67 Pen Plant * 3,713.17 Non Pen 3,383.91 Non Pen Total ₹ 4,431.26 Lakhs Total ₹ 5,740.84 Lakhs *Penecillin products’ demand was lower due to COVID-19. However,
Slide 15: Way Forward
Way Forward 14 Developments of products and dossiers Automisation of manufacturing and packaging To actively participate in line to increase output of various tenders in the Regulated markets Non-Regulated markets African region and add finished products, efficiency 4 dossiers filed in Q4 54 dossier
Slide 16: Financial Performance
15 Financial Performance
Slide 17: Financial Highlights: Quarterly Snapshot
Financial Highlights Quarterly Snapshot 16 Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs) 2,668.19 2432.33 2,535.46 2,363.45 14,454.98 12,440.21 12,454.44 11,630.41 8,755.77 1,108.23 Q-4 Q-1 Q-2 Q-3 Q-4 Q-4 Q-1 Q-2 Q-3 Q-4 2019-20 2020-21 2020-21 2020-21 2020-21 2019-20 2020-21 2020-21 2020-21 2020
Slide 18: Financial Highlights: Y-o-Y Snapshot
Financial Highlights Y-o-Y Snapshot 17 Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs) 50,980.04 9,999.43 36,095.99 36,013.01 32,947.82 32,430.42 4,040.17 3,841.47 3,308.51 3,139.82 2016-17 2017-18 2018-19 2019-20 2020-21 2016-17 2017-18 2018-19 2019-20 2020-21 *EBIDTA including other incomes Net Pr
Slide 19: Financial Ratios
Financial Ratios Building Shareholder Value Year on Year… 18 EBDITA & EBDITA Margin (₹ Lakhs, %) RoE (%) Total Debt/Equity (X) RoCE (%) 19.61% 9,999.43 0.71 29.9 0.57 0.51 11.19% 10.67% 0.41 10.04% 9.68% 25.23 3,139.82 4,040.17 3,841.47 15.3 3,308.51 12.71 14.5 0.26 12.23 15.95 14.1 14.2 11.18 2016-
Slide 20: Consolidated Financial Highlights
Consolidated Financial Highlights 19 (₹ Lakhs) Particulars FY 2020-21 FY 2019-20 FY 2018-19 FY 2017-18 Equity Share Capital 4,325.16 4,324.89 4,324.89 4,324.89 Other Equity 20,177.88 14,643.12 12,522.68 10,145.94 Networth 24,503.04 18,968.01 16,847.57 14,470.83 Fixed Assets (net) 15,508.37 14,139.16
Slide 21: Governance: Board of Directors
Governance Board of Directors 20 Mr. Surendra Somani Mr. Adarsh Rajendra Somani Mrs. Mamta Biyani Mr. Narayan Atal Executive Vice Chairman Director Independent Director Independent Director Dr. Siddhan Subramanian Dr. Sunita Banerji Mr. Susheel Somani Mr. Varun Surendra Somani Independent Director I
Slide 22: Ownership Structure
Ownership Structure 21 Kopran Shareholding Pattern (%) Limited 2.41 Kopran Research Kopran Laboratories Kopran (H.K.) Lifesciences Limited* Limited 43.78 Limited 53.82 Kopran (UK) Limited Promoters Non-Institutions Financial Institutions
Slide 23: Contact Us
Contact Us 22 About Kopran Limited: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Develop
Slide 24: Thank You
Thank You